CY-QUANT VASP/P2Y12

Retour à la liste

default
Référence
7502
Statut
CE
Sample
160 µl de sang total citraté
Quantité
1 to 23 tests/run
Detection
ELISA
Application
Kit ELISA
Composition

Microplaque coatée, PGE1, PGE1 + ADP, Tampon de lyse, Solution de lavage, Tampon de dilution, Anti-VASP-P-peroxydase, Solution stop, outil pour extraction des puits de leur barrette support

CY-QUANT VASP/P2Y12 est dédiée au dosage des antagonistes spécifiques du récepteur plaquettaire à l’ADP, P2Y12. La protéine intra-plaquettaire VASP (Vasodilator Stimulated Phosphoprotein) est non phosphorylée à l’état basal. La prostaglandine E1 (PGE1) induit la phosphorylation de VASP tandis que la fixation de l'adénosine diphosphate (ADP) sur les récepteurs P2Y12 entraîne la déphosphorylation de VASP. Dans les conditions du test et lors de l'ajout simultané de PGE1 et d'ADP, l'effet de l'ADP prévaut et induit la déphosphorylation de VASP, à moins que le récepteur P2Y12 soit efficacement bloqué par des drogues anti-plaquettaires ciblant ce récepteur (comme les thiénopyridines). Le niveau de phosphorylation de VASP dans cette condition reflète donc le niveau d'inhibition du récepteur P2Y12.

Date Nom du document Téléchargement
01/12/2017 Package insert CY-QUANT VASP P2Y12 DE (144.01 KB)
EN (131.77 KB)
ES (134.38 KB)
FR (135.60 KB)
IT (132.75 KB)
PT (135.36 KB)
01/09/2013 Flyer CY-QUANT VASP P2Y12 EN (726.86 KB)
Auteur Titre Année d'édition Revue
Barragan P. et al
Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity
2010
Thromb. Haemost
Jakubowski J.A. et al
Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated
2012
Thromb. Haemost
Abtan J et al
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein
2013
Thromb Haemost
Hobl E.L et al
Comparison of a new ELISA-based with the flow cytometric assay for vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation to assess P2Y12-inhibition after ticagrelor intake
2013
Cytometry
Gaussem P et al.
Inefficacy of Platelet Transfusion to Reverse Ticagrelor
2015
N Engl J Med
Söderlund et al
In vitro anti-platelet potency of ticagrelor in blood samples from infants and children
2015
Thromb Research
Bonello L et al
Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome
2015
Thromb Haemost
Umemura K & Iwaki T.
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
2016
Clin Pharmacol Drug Dev
Singh D. & Silakari O.
Facile alkylation of 4-nitrobenzotriazole and its platelet aggregation inhibitory activity
2017
Bioorg. Med. Chem.
Ding P. et al.
Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population
2017
Clin Appl Thromb Hemost.
Deharo P. et al
Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study
2017
JACC Cardiovasc Interv.
Takehiko Nagao et al
A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial – PRASTRO-I trial
2018
Expert Opinion on Pharmacotherapy
Deepak L. Bhatt et al
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
2019
The New England Journal of Medicine
Holm M. et al
The MOVEMENT Trial
2019
Journal of the American Heart Association
Ito Y. et al
Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats.
2018
International Journal of Scientific Reports
Bonello L. et al
Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients.
2017
Thrombosis Research
Zeymer U. et al
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention
2015
JACC: Cardiovascular Interventions
Martin A. et al.
Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach
2020
Eur J Pharmacol.